Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study

Table 5 Changes in blood cell counts and uric acid

Parameters	Dapagliflozin group	Metformin group	P value
White blood cell count (/μL)
Baseline	6378.6 ± 1553.5 (36)	6405.0 ± 1507.6 (36)	0.94
Week 16	6532.5 ± 1646.0 (35)	6372.6 ± 1700.5 (34)	0.69
Change	103.8 ± 1166.7 (34)	−106.2 ± 1183.0 (34)	0.46
P value within group	0.61	0.60	0.95
Red blood cell count (×10⁴/μL)
Baseline	468.9 ± 40.2 (36)	468.3 ± 41.8 (36)	<0.001
Week 16	493.6 ± 41.6 (35)	456.6 ± 42.9 (34)	<0.001
Change	26.3 ± 16.3 (34)	−12.0 ± 17.5 (34)
P value within group	<0.001	<0.001
Hemoglobin (g/dL)
Baseline	14.3 ± 1.3 (36)	14.4 ± 1.3 (36)	0.70
Week 16	14.9 ± 1.4 (35)	14.2 ± 1.7 (34)	0.05
Change	0.7 ± 0.5 (34)	−0.2 ± 0.9 (34)	<0.001
P value within group	<0.001	0.21
Hematocrit (%)
Baseline	42.6 ± 3.6 (36)	42.7 ± 3.3 (36)	0.94
Week 16	44.7 ± 3.5 (35)	41.8 ± 3.6 (34)	0.001
Change	2.2 ± 1.4 (34)	−0.9 ± 1.8 (34)	<0.001
P value within group	<0.001	0.006
Platelet count (×10⁴/μL)
Baseline	24.0 ± 6.4 (36)	24.0 ± 5.0 (36)	0.99
Week 16	23.9 ± 6.3 (35)	24.5 ± 4.7 (34)	0.64
Change	−0.3 ± 1.5 (34)	0.5 ± 2.2 (34)	0.09
P value within group	0.20	0.25
Uric acid (mg/dL)
Baseline	5.6 ± 1.1 (37)	5.8 ± 1.2 (37)	0.41
Week 16	4.9 ± 1.1 (36)	5.9 ± 1.1 (36)	<0.001
Change	−0.6 ± 0.7 (36)	0.1 ± 0.6 (36)	<0.001
P value within group	<0.001	0.43

Data are mean ± standard deviation (n). P values show results of comparisons between groups by t test. P values within groups are results of paired t test

ISSN: 1475-2840